MedTrace Logo

Pharmacological Postconditioning During the Aortic Valvular Surgery

NCT00987207 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2019-05-28

No results posted yet for this study

Summary

Primary objective: To evaluate the efficacy of the cyclosporin A administration to induce a cardioprotection during the valvular surgery.

Conditions

  • Aortic Valvular Surgery

Interventions

DRUG

cyclosporine A

a single bolus of 2.5 mg/kg, administered before aortic cross-declamping

OTHER

No injection

No cyclosporine A is administered before aortic cross-declamping.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Pascal CHIARI, MD · Hospices Civils de Lyon, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987207 on ClinicalTrials.gov